The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Feher, C
  • Munez Rubio, E.
  • Merino Amador, P.
  • Delgado-Iribarren Garcia-Campero, A.
  • Merino, E
  • Diaz-Brito, V
  • Alvarez, MJ
  • Mensa, J

Grupos

Abstract

The objective of this study was to evaluate the efficacy and safety of fidaxomicin in the real-life clinical setting. This was a retrospective cohort of patients with Clostridium difficile infection (CDI) treated with fidaxomicin in 20 Spanish hospitals between July 2013 and July 2014. Clinical cure, 30-day recurrence, 30-day mortality, sustained cure, and factors associated with the failure to achieve sustained cure were analyzed. Of the 72 patients in the cohort 41 (56.9 %) had a fatal underlying disease. There were 44 (61.1 %) recurrent episodes and 26 cases (36.1 %) with a history of multiple recurrences. Most episodes were severe (26, 36 %) or severe-complicated (14, 19.4 %). Clinical cure rate was 90.3 %, recurrence rate was 16.7 % and three patients (4.2 %) died during the follow-up period. Sustained cure was achieved in 52 cases (72.2 %). Adverse events were reported in five cases (6.9 %). Factors associated with the lack of sustained cure were cardiovascular comorbidity (OR 11.4; 95 %CI 1.9-67.8), acute kidney failure (OR 7.4; 95 %CI 1.3-43.1), concomitant systemic antibiotic treatment (OR 6.2; 95 %CI 1.1-36.8), and C-reactive protein value at diagnosis (OR 1.2 for each 1 mg/dl increase; 95 %CI 1.03-1.3). Fidaxomicin is an effective and well tolerable treatment for severe CDI and for cases with elevated recurrence risk.

Datos de la publicación

ISSN/ISSNe:
0934-9723, 1435-4373

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES  SPRINGER

Tipo:
Article
Páginas:
295-303
PubMed:
27718071
Factor de Impacto:
1,312 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 20

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • RISK-FACTORS; CO-MORBIDITY; VANCOMYCIN; PREDICTORS; METAANALYSIS; SUSCEPTIBILITY; MANAGEMENT; VALIDATION; GUIDELINES; DERIVATION

Cita

Compartir